Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3115]

Improving efficacy and toxicity reporting - and treatment insights from an...

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC...

Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression ( Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil...

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF...

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Key updates on breast cancer treatments from ASCO 2025

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Key updates on breast cancer treatments from ASCO 2025 ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Updates on gastrointestinal cancer treatments ASCO 2025

Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA

Updates on gastrointestinal cancer treatments ASCO 2025 ( Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA )

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

More from ecancer